CardiAI develops diagnostic devices and software that leverage algorithms for real-time analysis of cardiovascular health data. This technology enhances early detection of heart conditions, improving patient outcomes and alleviating pressure on healthcare systems.
Funding
$73.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods of cardiovascular health monitoring often lack the ability to provide real-time analysis and early detection of potential issues. This can lead to delayed diagnoses and interventions, potentially impacting patient outcomes and increasing the strain on healthcare resources.
Solution
CardiAI develops diagnostic devices and software solutions that utilize AI algorithms for the real-time analysis of cardiovascular health data. Their offerings include ambulatory blood pressure monitors (ABPM) and cardiac troponin I (cTnI) testing, enabling early detection of myocardial damage and accurate diagnosis of acute coronary syndrome (ACS). The company's technology facilitates risk stratification, monitors treatment efficacy, and provides prognostic value in both cardiac and non-cardiac conditions. CardiAI aims to improve patient outcomes through efficient and cost-effective smart triaging management.
Target Audience
CardiAI's primary customers include healthcare providers, hospitals, and research institutions focused on cardiology, as well as individuals seeking convenient and accessible cardiovascular health monitoring solutions.
Features
- BPAro 24-hour ambulatory blood pressure monitor (ABPM) for continuous blood pressure monitoring.
- Cardiac Troponin I (cTnI) testing for early detection of myocardial damage.
- Colorimetric lateral flow assay for rapid results in point-of-care settings.
- AI-powered algorithms for real-time analysis of cardiovascular data.
- Virtual care services for remote patient monitoring and support.
- CoviLamp PCR test with a viral detection limit of 3.125 copies/microliter.